Compare AGNC Investment Corp (AGNC) vs Amphastar Pharmaceuticals Inc (AMPH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AGNC Investment Corp vs Amphastar Pharmaceuticals Inc — how do they compare? AGNC Investment Corp trades at $10.9 (market cap $12.74B), while Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M). The key difference: AGNC Investment Corp is far larger — about 14.7× Amphastar Pharmaceuticals Inc's market cap, and AGNC Investment Corp pays a 13.4% dividend while Amphastar Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AGNC | AMPH | |
|---|---|---|
Market Cap | $12.74B | $863.95M |
Sector | Financials | Health |
52-Week High | $12.17 | $30.81 |
52-Week Low | $9.46 | $16.87 |
Dividend Yield | 13.4% | — |
Enterprise Value | — | $1.26B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AGNC Investment trades at $10.84, up 2.17% today, with a bullish technical signal and strong earnings beats in Q1 and Q2 2026. The stock offers a high dividend yield, with consistent monthly payouts, and trades at a P/E of 5.39 and P/B of 1.22. Recent news highlights its 13%+ yield and stable dividend history, though analyst consensus is mixed with a Hold majority.
Outlook remains positive due to robust net income margins above 94% and economic returns, but risks include interest rate sensitivity and leveraged mortgage securities. The consensus price target of $11.30 suggests modest upside, supported by institutional interest and earnings momentum, though volatility from macroeconomic factors warrants caution.
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About AGNC Investment Corp
AGNC Investment Corp is a real estate investment trust that invests in agency residential mortgage-backed securities. The firm's asset portfolio is comprised of residential mortgage pass-through securities and collateralized mortgage obligations for which the principal and interest payments are guaranteed by a U.S. Government-sponsored enterprise, such as the Federal National Mortgage Association and the Federal Home Loan Mortgage Corporation, or by a U.S. Government agency, such as the Government National Mortgage Association. It also invests in other types of mortgage and mortgage-related residential and commercial mortgage-backed securities or other investments in or related to, the housing, mortgage or real estate markets.
Read more on AGNC →About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →
